Dr. Caio Max Rocha-Lima reviewed 2025 advances in pancreatic, hepatic, and cholangiocarcinoma care. Pre-op therapies showed improved survival, with Pax G outperforming FOLFIRINOX in the Cassandra trial. Panova 3 spotlighted a survival-boosting device. NCCN now backs neoadjuvant care for all risk groups.